페니트리움바이오 분기보고서 (2024.09)
1. 요약재무정보

1) 요약연결재무정보(단위: 원)

구분	제23기 당분기말 (2024년 09월말)	제22기 전기말 (2023년 12월말)	제21기 전전기말 (2022년 12월말)

[유동자산]	13,659,305,707	25,555,266,153	40,589,451,279

ㆍ현금및현금성자산	8,852,309,029	3,372,575,210	3,097,124,698

ㆍ단기금융상품	760,635,185	15,601,000,000	24,000,000,000

ㆍ당기손익-공정가치측정금융자산	-	-	7,972,804,866

ㆍ매출채권및기타채권	3,426,039,119	4,829,834,701	3,985,136,066

ㆍ재고자산	-	1,162,854,413	402,481,233

ㆍ기타유동자산	620,322,374	589,001,829	1,131,904,416

[비유동자산]	16,464,572,175	18,658,927,574	5,702,953,933

ㆍ관계기업투자주식	888,184,558	871,971,044	952,060,316

ㆍ당기손익-공정가치측정비유동금융자산	1,019,373,400	974,520,000	224,364,912

ㆍ유형자산	1,144,021,268	2,849,220,036	2,792,157,646

ㆍ무형자산	973,193,591	1,081,519,184	973,401,615

ㆍ투자부동산	11,564,840,202	11,720,483,348	-

ㆍ기타비유동자산	874,959,156	1,161,213,962	760,969,444

자산총계	30,123,877,882	44,214,193,727	46,292,405,212

[유동부채]	19,541,942,359	15,296,655,852	14,207,021,960

[비유동부채]	1,527,800,320	1,789,955,526	1,375,585,374

부채 총계	21,069,742,679	17,086,611,378	15,582,607,334

지배기업소유주지분	9,630,569,278	27,150,789,792	30,340,609,792

[자본금]	2,183,625,000	2,183,625,000	2,183,625,000

[자본잉여금]	20,418,648,438	20,418,648,438	20,418,648,438

[기타자본]	(3,719,693,353)	(3,727,813,651)	(3,723,279,478)

[이익잉여금]	(9,252,010,807)	8,276,330,005	11,461,615,832

비지배지분	(576,434,075)	(23,207,443)	369,188,086

자본 총계	9,054,135,203	27,127,582,349	30,709,797,878

관계기업 투자주식의 평가방법	지분법	지분법	지분법

2024.01.01~2024.09.30	2023.01.01~2023.12.31	2022.01.01~2022.12.31

매출액	7,603,670,527	13,790,195,699	14,882,555,787

영업이익	(14,916,965,293)	(3,464,613,885)	(754,740,449)

당기순이익	(18,004,091,975)	(3,363,294,388)	(58,882,743)

지배기업소유주지분	(17,441,502,027)	(2,970,313,225)	266,502,935

비지배지분	(562,589,948)	(392,981,163)	(325,385,678)

주당순이익	(825)	(140)	12

희석주당이익	(579)	(87)	3

2) 요약재무정보(단위: 원)

구분	제23기 당분기말 (2024년 09월말)	제22기 전기말 (2023년 12월말)	제21기 전전기말 (2022년 12월말)

[유동자산]	13,458,520,110	26,416,763,716	39,845,619,438

ㆍ현금및현금성자산	8,698,868,114	3,326,420,831	3,084,101,544

ㆍ단기금융상품	760,635,185	15,601,000,000	24,000,000,000

ㆍ당기손익-공정가치측정금융자산	-	-	7,972,804,866

ㆍ매출채권및기타채권	3,423,590,059	6,775,291,022	3,726,662,122

ㆍ기타유동자산	575,426,752	714,051,863	1,062,050,906

[비유동자산]	15,600,470,690	18,179,783,943	7,078,266,068

ㆍ당기손익-공정가치측정비유동금융자산	1,019,373,400	974,520,000	224,364,912

ㆍ종속기업투자주식	-	1,907,636,272	3,815,272,544

ㆍ관계기업투자주식	743,773,620	743,773,620	743,773,620

ㆍ유형자산	1,144,021,268	1,368,990,257	1,461,088,871

ㆍ무형자산	253,503,044	266,663,505	64,383,068

ㆍ투자부동산	11,564,840,202	11,720,483,348	-

ㆍ기타비유동자산	874,959,156	1,197,716,941	769,383,053

자산총계	29,058,990,800	44,596,547,659	46,923,885,506

[유동부채]	19,502,632,339	15,144,738,418	13,934,446,459

[비유동부채]	659,174,188	661,875,854	182,535,087

부채 총계	20,161,806,527	15,806,614,272	14,116,981,546

[자본금]	2,183,625,000	2,183,625,000	2,183,625,000

[자본잉여금]	21,395,991,395	21,395,991,395	21,395,991,395

[기타자본]	(3,739,155,755)	(3,739,155,755)	(3,739,155,755)

[이익잉여금]	(10,943,276,367)	8,949,472,747	12,966,443,320

자본 총계	8,897,184,273	28,789,933,387	32,806,903,960

종속,관계투자주식의 평가방법	원가법	원가법	원가법

2024.01.01~2024.09.30	2023.01.01~2023.12.31	2022.01.01~2022.12.31

매출액	7,305,056,011	13,790,195,699	14,881,305,787

영업이익	(14,102,328,200)	(1,911,004,834)	516,521,349

당기순이익	(19,776,980,208)	(3,800,188,519)	1,144,040,937

주당순이익	(935)	(180)	53

희석주당이익	(672)	(124)	42